Literature DB >> 31588408

Risk factors for the development of idiopathic pulmonary fibrosis: A review.

Tanzira Zaman1, Joyce S Lee1.   

Abstract

PURPOSE OF REVIEW: Idiopathic pulmonary fibrosis (IPF) is an invariably progressive disease. Current treatment options simply slow disease progression and better therapeutic options are needed. We aimed to review emerging literature on risk factors associated with the development of IPF. RECENT
FINDINGS: There is increasing data to support the role of intrinsic risk factors (e.g. genetics, aging, sex, lung microbiome), co-morbidities (e.g. gastroesophageal reflux, obstructive sleep apnea, diabetes mellitus, herpes virus infection), and extrinsic risk factors (e.g. cigarette smoking, environmental exposures, air pollution) in IPF development. These risk factors may independently increase susceptibility for IPF or act in a synergistic fashion to contribute to increased risk for disease development.
SUMMARY: Various risk factors have been identified in IPF development that fit within the current paradigm of disease pathogenesis. Further investigation in to these risk factors may help us better understand the pathophysiology of IPF and may guide future therapeutic interventions.

Entities:  

Keywords:  Aging; cigarette smoking; gastroesophageal reflux; genetics; obstructive sleep apnea

Year:  2018        PMID: 31588408      PMCID: PMC6777743          DOI: 10.1007/s13665-018-0210-7

Source DB:  PubMed          Journal:  Curr Pulmonol Rep


  91 in total

Review 1.  Is idiopathic pulmonary fibrosis an environmental disease?

Authors:  Varsha S Taskar; David B Coultas
Journal:  Proc Am Thorac Soc       Date:  2006-06

2.  Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis.

Authors:  K B Baumgartner; J M Samet; C A Stidley; T V Colby; J A Waldron
Journal:  Am J Respir Crit Care Med       Date:  1997-01       Impact factor: 21.405

3.  A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation.

Authors:  Surafel Mulugeta; Vu Nguyen; Scott J Russo; Madesh Muniswamy; Michael F Beers
Journal:  Am J Respir Cell Mol Biol       Date:  2005-03-18       Impact factor: 6.914

4.  Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.

Authors:  Helen E Jo; Ian Glaspole; Christopher Grainge; Nicole Goh; Peter M A Hopkins; Yuben Moodley; Paul N Reynolds; Sally Chapman; E Haydn Walters; Christopher Zappala; Heather Allan; Gregory J Keir; Andrew Hayen; Wendy A Cooper; Annabelle M Mahar; Samantha Ellis; Sacha Macansh; Tamera J Corte
Journal:  Eur Respir J       Date:  2017-02-23       Impact factor: 16.671

5.  The association between air pollution and the incidence of idiopathic pulmonary fibrosis in Northern Italy.

Authors:  Sara Conti; Sergio Harari; Antonella Caminati; Antonella Zanobetti; Joel D Schwartz; Pietro A Bertazzi; Giancarlo Cesana; Fabiana Madotto
Journal:  Eur Respir J       Date:  2018-01-25       Impact factor: 16.671

6.  Alveolar epithelial cell injury with Epstein-Barr virus upregulates TGFbeta1 expression.

Authors:  Andrea P Malizia; Dominic T Keating; Sinead M Smith; Dermot Walls; Peter P Doran; Jim J Egan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-11       Impact factor: 5.464

7.  Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis.

Authors:  Akihito Yokoyama; Keiichi Kondo; Masamitsu Nakajima; Toshiharu Matsushima; Toru Takahashi; Masaharu Nishimura; Masashi Bando; Yukihiko Sugiyama; Yoshitaka Totani; Takeshi Ishizaki; Hidenori Ichiyasu; Moritaka Suga; Hironobu Hamada; Nobuoki Kohno
Journal:  Respirology       Date:  2006-03       Impact factor: 6.424

8.  Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer.

Authors:  Nadia Nathan; Violaine Giraud; Clément Picard; Hilario Nunes; Florence Dastot-Le Moal; Bruno Copin; Laurie Galeron; Alice De Ligniville; Nathalie Kuziner; Martine Reynaud-Gaubert; Dominique Valeyre; Louis-Jean Couderc; Thierry Chinet; Raphaël Borie; Bruno Crestani; Maud Simansour; Valérie Nau; Sylvie Tissier; Philippe Duquesnoy; Lamisse Mansour-Hendili; Marie Legendre; Caroline Kannengiesser; Aurore Coulomb-L'Hermine; Laurent Gouya; Serge Amselem; Annick Clement
Journal:  Hum Mol Genet       Date:  2016-01-19       Impact factor: 6.150

9.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis.

Authors:  David N O'Dwyer; Michelle E Armstrong; Glenda Trujillo; Gordon Cooke; Michael P Keane; Padraic G Fallon; A John Simpson; Ann B Millar; Emmet E McGrath; Moira K Whyte; Nik Hirani; Cory M Hogaboam; Seamas C Donnelly
Journal:  Am J Respir Crit Care Med       Date:  2013-12-15       Impact factor: 21.405

View more
  14 in total

1.  Molecular mapping of interstitial lung disease reveals a phenotypically distinct senescent basal epithelial cell population.

Authors:  Daryle J DePianto; Jason A Vander Heiden; Katrina B Morshead; Kai-Hui Sun; Zora Modrusan; Grace Teng; Paul J Wolters; Joseph R Arron
Journal:  JCI Insight       Date:  2021-04-22

2.  Idiopathic pulmonary fibrosis and gastroesophageal reflux disease: A population-based, case-control study.

Authors:  Misbah Baqir; Amit Vasirreddy; Ann N Vu; Teng Moua; Alanna M Chamberlain; Ryan D Frank; Jay H Ryu
Journal:  Respir Med       Date:  2021-01-22       Impact factor: 4.582

Review 3.  NADPH oxidases: Pathophysiology and therapeutic potential in age-associated pulmonary fibrosis.

Authors:  Kosuke Kato; Louise Hecker
Journal:  Redox Biol       Date:  2020-04-17       Impact factor: 11.799

Review 4.  "A Chain Only as Strong as Its Weakest Link": An Up-to-Date Literature Review on the Bidirectional Interaction of Pulmonary Fibrosis and COVID-19.

Authors:  Radu Crisan-Dabija; Cristina Alice Pavel; Iolanda Valentina Popa; Andrei Tarus; Alexandru Burlacu
Journal:  J Proteome Res       Date:  2020-09-17       Impact factor: 4.466

5.  Hsa_circ_0044226 knockdown attenuates progression of pulmonary fibrosis by inhibiting CDC27.

Authors:  Fei Qi; Yong Li; Xue Yang; Yanping Wu; Lianjun Lin; Xinmin Liu
Journal:  Aging (Albany NY)       Date:  2020-07-24       Impact factor: 5.682

6.  Post-discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission.

Authors:  Laurent Truffaut; Lucas Demey; Anne Violette Bruyneel; Alain Roman; Stephane Alard; Nathalie De Vos; Marie Bruyneel
Journal:  Respir Res       Date:  2021-01-21

Review 7.  Obesity and the Development of Lung Fibrosis.

Authors:  Xia Guo; Christudas Sunil; Guoqing Qian
Journal:  Front Pharmacol       Date:  2022-01-10       Impact factor: 5.810

Review 8.  Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis.

Authors:  Thị Hằng Giang Phan; Panagiotis Paliogiannis; Gheyath K Nasrallah; Roberta Giordo; Ali Hussein Eid; Alessandro Giuseppe Fois; Angelo Zinellu; Arduino Aleksander Mangoni; Gianfranco Pintus
Journal:  Cell Mol Life Sci       Date:  2020-11-17       Impact factor: 9.261

Review 9.  Regulation of cellular senescence by extracellular matrix during chronic fibrotic diseases.

Authors:  Kaj E C Blokland; Simon D Pouwels; Michael Schuliga; Darryl A Knight; Janette K Burgess
Journal:  Clin Sci (Lond)       Date:  2020-10-30       Impact factor: 6.124

Review 10.  Idiopathic Pulmonary Comorbidities and Mechanisms.

Authors:  Maricica Pacurari; Amal Mitra; Timothy Turner
Journal:  Int J Inflam       Date:  2021-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.